FDA 361 HCT/P Compliance Audit Checklist for Clinics

An FDA 361 HCT/P compliance audit checklist for regenerative medicine clinics evaluates four core operational domains: vendor registration and donor eligibility documentation, cold chain and storage logs, lot-to-patient traceability for adverse event reporting, and external marketing alignment with homologous use standards. While tissue banks bear primary manufacturing oversight under 21 CFR Part 1271, outpatient clinics that procure, store, and administer human cells, tissues, and cellular and tissue-based products (HCT/Ps) must maintain auditable standard operating procedures (SOPs) to mitigate regulatory, legal, and supply-chain risk. Practice administrators can use the operational checklist below to audit existing workflows and evaluate prospective biologic distributors before onboarding.

Understanding the 361 HCT/P Framework at the Clinic Level

For a medical practice manager, navigating the regulatory landscape of regenerative products requires distinguishing between two primary pathways under the Public Health Service (PHS) Act: Section 361 and Section 351.

To qualify as a 361 HCT/P—which does not require premarket drug or biologics license approval—a product must meet all four criteria outlined in 21 CFR 1271.10(a):

• Minimal manipulation: Processing must not alter the original relevant characteristics of structural tissue (such as Wharton's Jelly or amniotic membrane) or the relevant biological characteristics of cells.
• Homologous use: The product must perform the same basic function or functions in the recipient as in the donor, as reflected in labeling, advertising, and objective intent.
• No combination with other articles: With limited exceptions for water, crystalloids, or sterilizing, preserving, or storage agents.
• No systemic effect or dependence on metabolic activity of living cells: Unless the product is for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.

When a clinic purchases regenerative biologics from a tissue bank or distributor, the clinic's operational compliance depends on verifying that the upstream manufacturer maintains valid registrations and that the clinic's own storage, handling, and promotional practices do not inadvertently reclassify a product into the 351 drug pathway.

The Operational Compliance Audit Checklist

Practice administrators should conduct an internal audit of their biologic procurement and handling protocols on a scheduled cadence (typically quarterly or semi-annually). Use the following checklist to evaluate your current documentation and workflow readiness.

1. Vendor Qualification and Procurement Files

Before ordering any allograft tissue, exosomes, or umbilical cord-derived products, the practice manager should maintain a permanent vendor qualification file containing:

• Active FDA Establishment Registration (FEI Number): Verify the source tissue bank's registration status directly through the FDA Human Cell and Tissue Establishment Registration (HCTERS) public database. Note that registration is annual; confirm the certificate is current for the calendar year.
• State Distributor and Tissue Bank Licenses: Ensure the tissue processor and any intermediary distributor hold appropriate state-level licensure (for example, Texas medical device distributor licensing or state-specific tissue bank permits in states like California, New York, or Florida).
• Accreditation Verification: Document whether the processing lab holds voluntary accreditation from recognized bodies such as the American Association of Tissue Banks (AATB), which indicates adherence to established quality systems.
• Product Insert and Regulatory Designation: Retain a copy of the official package insert for every SKU in inventory. Review how the manufacturer characterizes the product's regulatory status and intended function.

2. Donor Eligibility and Lot-Level Documentation

Every shipment of allogeneic tissue entering your facility must be accompanied by lot-specific documentation. Your receiving workflow should require staff to verify and file:

• Summary of Records / Certificate of Analysis (CoA): Confirm that each lot includes a statement of donor eligibility determination based on donor screening and infectious disease testing under 21 CFR Part 1271 Subpart C.
• Communicable Disease Testing Verification: Confirm that the documentation explicitly lists negative or non-reactive results for required relevant communicable disease agents and diseases (RCDADs), including HIV-1/2, Hepatitis B, Hepatitis C, Treponema pallidum (syphilis), and HTLV-I/II where applicable.
• Sterility and Endotoxin Testing: Verify whether lot release criteria include USP sterility and endotoxin testing before the product is placed into active clinical inventory.
• Tissue Tracking and Recipient Record Cards: Ensure the staff completes and returns manufacturer tissue tracking records (either via secure portal or physical card) linking the specific lot and serial number to your facility.

3. Cold Chain, Receiving, and Storage Logs

Improper temperature control compromises tissue integrity and invalidates manufacturer specifications. Audit your back-office clinical space for the following controls:

• Shipping Validation Upon Receipt: Require the receiving medical assistant or inventory coordinator to inspect the shipping container upon arrival, confirm dry ice or phase-change pack integrity, and record the arrival condition on a receiving log.
• Calibrated Temperature Monitoring: Maintain continuous, calibrated digital temperature data loggers on all refrigerators, standard freezers, and ultra-low temperature (ULT) cryofreezers used to store biologics.
• Daily Temperature Logs and Excursion SOPs: Verify that staff document daily min/max temperatures (or review automated cloud alerts) and that a written standard operating procedure exists for quarantining inventory if a temperature excursion occurs.
• Segregated Quarantine Space: Maintain a clearly labeled physical quarantine zone inside your storage unit for expired, recalled, or temperature-compromised units awaiting disposition.

4. EHR Traceability and Adverse Event Reporting Workflows

In the event of a tissue recall or a suspected adverse reaction, the clinic must be able to identify affected patients immediately. Audit your charting and incident protocols for:

• Bidirectional Lot Traceability: Confirm that your Electronic Health Record (EHR) or dedicated biologic inventory log allows you to search by a single lot number and immediately generate a list of every patient who received tissue from that lot.
• Standardized Charting Fields: Ensure clinical templates capture the exact product name, manufacturer, lot/serial number, expiration date, preparation method, anatomical site, and staff member who prepared the tissue.
• Adverse Reaction Investigation SOP: Maintain a written protocol instructing staff on how to document, escalate, and report any suspected communicable disease transmission or severe adverse reaction to both the source tissue bank and MedWatch.
• Informed Consent Alignment: Review patient informed consent forms with legal counsel to verify they accurately describe the nature of the tissue (e.g., allogeneic vs. autologous), known risks, and alternative therapies without promising guaranteed clinical outcomes.

5. Website, Social Media, and Patient Education Audit

Under 21 CFR 1271.10(a)(2), the FDA evaluates "objective intent" not only by what a manufacturer prints on a label, but also by how a clinic markets the product to patients. Administrators should audit all patient-facing assets:

• Elimination of Disease-Treatment Claims: Audit website pages, landing pages, paid digital ads, and printed brochures to ensure no unapproved disease-specific cure or treatment claims are made for unapproved HCT/Ps.
• Homologous Function Language: Ensure descriptions of structural tissues focus on structural roles (such as cushioning, barrier support, or structural supplementation) rather than systemic pharmacological claims.
• Before-and-After and Testimonial Review: Verify that patient testimonials do not make implied regulatory claims that the practice itself cannot legally substantiate.

Clinical vs. Operational Perspective: Bridging Physician Intent and Practice Risk

While the practice manager focuses on documentation, cold chain, and marketing exposure, the treating physician approaches regenerative medicine from the standpoint of clinical mechanism, patient selection, and multimodal protocol design. Bridging these two perspectives is essential for a compliant and sustainable service line.

For regenerative medicine doctors and specialists in orthopedics or aesthetics, clinical outcomes often rely on combining autologous preparations—such as point-of-care Platelet-Rich Plasma (PRP)—with energy-based modalities like extracorporeal shockwave therapy (ECSWT) or high-power laser therapy. From a regulatory standpoint, autologous blood products like PRP are governed differently than human cells or tissues under Part 1271 (blood products used at the point of care typically fall under device clearances for the centrifugation system rather than HCT/P tissue rules, provided they are not manipulated beyond device labeling).

When physicians evaluate adding allogeneic tissues or medical devices to their treatment algorithms, the medical director and the practice administrator should conduct a joint review:

• Physician Role: Evaluates the peer-reviewed literature, anatomical applicability, preparation protocol, and clinical appropriateness for the individual patient.
• Administrator Role: Vets the distributor's supply chain credentials, verifies the tissue bank's FDA registration, integrates lot tracking into the EHR, and ensures the marketing team promotes the service line within regulatory boundaries.

By separating clinical decision-making from promotional overreach, practices protect both the physician's medical license and the enterprise value of the clinic.

What This Means for Your Practice

Building a durable regenerative medicine service line requires treating compliance as an operational asset rather than an administrative afterthought. Practice managers can take three concrete steps this week to strengthen their clinic's position:

1. Pull and verify your vendor binder: Locate the current FDA HCTERS registration printouts and Certificates of Analysis for every biologic SKU currently sitting in your freezer. If any documentation is missing or outdated, request updated records from your representative immediately.
2. Run a mock lot-trace drill: Select one biologic lot number administered in the past 90 days and time how long it takes your clinical coordinator to identify every patient who received a unit from that lot. If it takes more than a few minutes, upgrade your EHR charting fields or inventory log.
3. Audit your top three landing pages: Review your clinic's highest-traffic regenerative medicine web pages against the homologous use and disease-claim criteria, flagging any exuberant marketing copy for clinical and legal review.

Working with an established, licensed medical distributor simplifies vendor qualification and documentation management. If your practice is auditing its current biologic supply chain or evaluating compliant device and tissue partnerships, contact our team to schedule an operational consultation.